Medi-Tate develops new solutions for treating diseases of the urethra and prostate.

Its solutions are designed to reduce associated symptoms and significantly improve patients' quality of life.The Medi-Tate device offers patients relief from the symptoms of benign prostate hyperplasia (BPH).

The device is placed in the prostatic urethra for five days.

During this time, it pushes obstructive tissue to the side, reshaping the prostate to create a long-term therapeutic effect.The device can be deployed in any clinical setting with standard rigid cystoscopy equipment.

The deployment procedure is intuitive and does not require a postprocedural catheter.

Once the device is deployed, the patient is free to return to normal activities immediately.Medi-Tate's iTind system for the treatment of BPH is CE marked and available for sale in the European Union, Canada, Hong Kong, and Israel.

In April 2020, the company received an FDA De Novo classification for its iTind system.